Omnicell
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 months.
- Its last 4 Sell calls were followed by a 14% average decline over the next quarter.
- Recent price momentum is -6.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 8.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 33.9x | Better than 18% |
| Forward P/E | 36.5x | Better than 12% |
| Price / Sales | 1.3x | Better than 71% |
| P/E vs own 5-yr range | 35th pctl | Better than 71% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -2.9% | Better than 15% |
| Net income CAGR (3Y) | -28.6% | Better than 11% |
| Free cash flow CAGR (3Y) | 59.7% | Better than 87% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 42.5% | Better than 52% |
| Operating margin | 0.4% | Better than 22% |
| Net margin | 0.2% | Better than 26% |
| Return on equity | 0.2% | Better than 28% |
| Return on invested capital | 0.1% | Better than 29% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -8.6% | Better than 54% |
| 6-month return | -26.8% | Better than 21% |
| 12-month return (ex latest month) | 4.9% | Better than 40% |
| Distance below 52-week high | 40.9% | Better than 27% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.4x | Better than 38% |
| Debt to assets | 10.3% | Better than 69% |
| Interest coverage | 288.1x | Better than 96% |
| Free cash flow / net income | 3,380.5% | Better than 99% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 73.3% | Better than 77% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 33.18
- Open
- 32.93
- Day range
- 32.27 - 33.39
- Avg price
- 32.61
- Volume
- 564.53K
- Turnover
- 18.41M
- Turnover ratei
- 1.26%
- Volume ratioi
- 1.40
- Amplitudei
- 3.38%
- 52-week rangei
- 31.75 - 55.00
Valuation
- P/Ei
- 812.75
- P/E (TTM)i
- 33.86
- P/Bi
- 1.14
- EPSi
- 0.04
- Book value / shi
- 28.64
- Net profit
- 1.84M
- Net assets
- 1.32B
Share structure
- Market cap
- 1.50B
- Float capi
- 1.45B
- Shares out
- 46.00M
- Float sharesi
- 44.70M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
40.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.35M net over the window
Short interest
- Shares short
- 3.77M
- % of floati
- 8.27%
- Days to coveri
- 6.34
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Omnicell (OMCL)?
Omnicell last traded at 32.51. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Omnicell's market cap?
About 1.50B.
What is the P/E ratio of Omnicell?
The trailing twelve-month P/E is 33.86, below its own 5-year average of 69.74 — in the middle of its historical range (35.25% percentile). See the Valuation tab for the full history.
Does Omnicell pay a dividend?
Omnicell does not currently pay a regular dividend.
Is Omnicell a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 56.33, which implies 73.3% upside from the current price. This is not investment advice.
What is Omnicell's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Omnicell a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Omnicell discussion 0 comments